Both ixekizumab and secukinumab are monoclonal antibodies that specifically inhibit IL-17 A. However, a recent meta-analysis showed that ixekizumab improved the psoriasis area and severity index (PASI) significantly more than secukinumab over a 12-week course of treatment, which provides new insight into the selection of an appropriate IL-17 inhibitor (27). This evidence concerns the gene IL17A and psoriasis.